delta 9-cadherin targeting antibody (Actinium)

N/A

Report date: 2025/03/18 20:00:05

Base Information

Drug Namedelta 9-cadherin targeting antibody (Actinium)
Drug Alias Namebismuth-123-d9Mab
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugateRadiation-emitting products > Radioactive therapeutic agent
Mechanisms of ActionCadherin-1 modulators
TargetsCadherin-1
Therapy Area/IndicationsStomach Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermany
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesHelmholtz Zentrum Muenchen
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsStomach Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A